21CTP.LEUK01:Asciminib,Dasatinib,Prednisone,and Blinatumomab Newly Diagnosed Phila Chromo ALL

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Principal Investigator
Headshot of Harry Paul Erba
Professor of Medicine
Protocol Number
IRB: PRO00118445
NCT: NCT06773936
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL